)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Rigel Pharmaceuticals
Rigel Pharmaceuticals (RIGL) investor relations material
Rigel Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic objectives and business evolution
Four strategic objectives: grow commercial business, in-license/add products, advance pipeline, maintain financial discipline.
Transitioned from a single-product company in 2020 to three commercial products and four indications by 2025.
Achieved profitability in Q3 2024, generating $100 million in cash since then.
Plans to continue growth through 2030 by expanding the portfolio and advancing R289.
Sales grew 35% from 2022 to 2025, with a 41% year-over-year increase in Q4 2025.
Commercial product performance
TAVALISSE sales reached $45 million, with 47% growth and expanded use in earlier treatment lines.
GAVRETO sales increased from $7 million to over $10 million per quarter after acquisition.
REZLIDHIA, launched for relapsed/refractory IDH1+ AML, grew to nearly $10 million per quarter.
Inflation Reduction Act improved patient retention for TAVALISSE, smoothing revenue across quarters.
International partnerships drive additional revenue and market expansion.
Pipeline and R&D focus
R289 (IRAK1/4 inhibitor) is the lead pipeline asset, targeting low-risk MDS with promising early data.
Phase 1b study showed 33% response in heavily pretreated, transfusion-dependent patients at adequate doses.
Dose expansion phase ongoing; registrational study planned for 2027.
Exploring additional indications for R289, leveraging its unique mechanism and first-mover advantage.
Collaborations with MD Anderson, MyeloMATCH, and others to expand clinical data and indications.
R289's competitive edge in low-risk MDS?
What drives TAVALISSE's continued growth?
Criteria for future in-licensed products
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Rigel Pharmaceuticals earnings date
Q4 20253 Mar, 2026
Rigel Pharmaceuticals
Next Rigel Pharmaceuticals earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Rigel Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing small-molecule drugs for immune and hematologic disorders, as well as rare diseases. The company’s research and development efforts target critical pathways in the immune system to address conditions with significant unmet medical needs. Rigel also partners with other pharmaceutical companies to advance its therapeutic candidates. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage